HEPTA Medical funding news – Paris-based HEPTA Medical Secures €5.7 Million in Series A Round Funding

This financing round will enable HEPTA to initiate the US regulatory approval process for the first version of its microwave ablation platform and to commence its clinical trials. Lung cancer is the leading cause of cancer-related deaths worldwide.

Read also - Stockholm-based Tiptapp Raises €1 Million in Funding

As lung cancer screening programs are being implemented, the management of early-stage lung cancer patients has become an increasingly urgent concern for healthcare organizations. HEPTA aims to address this need by offering a controlled, incision-less technology, that provides a minimally invasive approach to treat patients quickly, safely, and efficiently.

Dr. Thomas Bancel, CEO of HEPTA Medical said, “We are grateful for our new investors, and excited to bring microwave ablation therapy to new heights. In August, we obtained our first proprietary patent, completing our three patent families under license. We have multiple upcoming milestones, including the release of early preclinical trial results conducted in collaboration with world-renowned centers, which we’ll publish at the CIRSE conference in September,”.

Philippe Boucheron, Deputy Chief of Life Sciences Investments at BPI France said, “We are thrilled to be part of HEPTA Medical’s journey as they push the boundaries of innovation in minimally invasive lung cancer treatment. This investment aligns with our commitment to support groundbreaking medical technologies that have the potential to significantly improve patient outcomes. HEPTA’s unique approach to thermal ablation therapy, combined with their dedicated team and cutting-edge technology, positions them at the forefront of transforming lung cancer care. We are confident that HEPTA Medical will achieve significant milestones in the near future and are excited to support their continued growth and success,”.

About HEPTA Medical

HEPTA Medical was founded in 2019 by Sofinnova medtech acceleration team, MD Start. HEPTA develops a flexible microwave ablation probe compatible with any lung navigation system. HEPTA Medical develops a flexible microwave ablation platform for the minimally-invasive treatment of early-stage lung cancer patients.

Its incision-less technology can deliver thermal energy through the airway. HEPTA Medical’s microwave ablation probe is equipped with a proprietary patented temperature sensor enabling to monitor and control the growth of the ablation zone during the procedure.